Norway · Delayed Price · Currency is NOK Oncoinvent ASA Earnings Call Transcripts
Fiscal Year 2026
-
Radspherin’s early trials showed encouraging efficacy signals and a strong safety profile, supporting a randomized ovarian cancer phase II now enrolling. Efficacy interim data are planned for April 2027; phase III could start as early as 2027 if results are positive.
-
Phase II enrollment reached 71 patients by end-Q3, with 11 active sites and Q4 recruitment tracking steadily. A NOK 148.5m raise extended runway into H2 2027 to support phase II completion and phase III preparation; safety data are planned before Christmas 2026 and efficacy data in April 2027.
-
Phase II ovarian cancer trial recruitment accelerated, surpassing the halfway mark with 55 patients and 10 active sites. Cash burn remains controlled, funding operations into 2027, while preparations for phase III and strategic partnerships are underway.
-
Phase II trial recruitment for Radspherin is progressing well, with 37 patients enrolled and cash reserves supporting operations into 2027. A new Chinese patent was secured, and strategic partnerships are being pursued to extend runway and advance to pivotal studies.
-
Shareholders approved a 100-to-1 reverse share split, reduction of nominal share value, and board authorizations for future capital increases. The meeting addressed rationale for these changes, future listing options, and ongoing recruitment updates, with all proposals passing.
Fiscal Year 2025
-
Positive phase I ovarian cancer data and strong phase II recruitment marked the period, supported by a NOK 130 million equity raise and a merger, resulting in a NOK 180 million year-end cash balance and a runway into 2027. Clinical expansion and strategic partnerships remain key priorities.
-
Shareholders approved all agenda items, including a share capital reduction and subsequent increase to facilitate a NOK 130 million rights issue at a new share price of NOK 0.5, with nearly unanimous support for all resolutions.
-
Phase I trials in ovarian and colorectal cancer showed strong safety and efficacy signals for Radspherin, with a merger and rights issue extending cash runway into 2027. Phase II ovarian cancer trial recruitment is accelerating, with interim data expected in 2026.
-
A merger will create a well-funded, publicly listed radiopharma company focused on peritoneal metastases, with BerGenBio shareholders owning 25% and Oncoinvent 75%. The deal secures funding into 2027, accelerates clinical milestones, and is backed by both boards and major shareholders.
Fiscal Year 2024
-
Phase II BGB016 study in first-line STK11-mutated NSCLC discontinued after interim results showed no meaningful efficacy, prompting a strategic review of assets and future options. Year-end cash was NOK 140 million, with a focus on cost control and potential transactions.
-
Phase 1b enrollment for Bemcentinib in STK11-mutated NSCLC is complete, with strong safety and therapeutic data. Cash burn remains below guidance, funding operations into Q3 2025. Interim Phase 2a results are expected in early 2025.
-
Advanced clinical development in STK11-mutated NSCLC with phase II-A on track and innovative synthetic control arm established. Strong cash position funds operations through summer 2025, with pivotal study planning underway and multiple data readouts expected in the coming year.